Rapid Micro Biosystems (RPID) Stifel 2024 Healthcare Conference summary

Business overview and market context

• Focused on automating microbial quality control in pharmaceutical manufacturing, modernizing a process that has seen little change in a century.

• Growth Direct platform automates legacy QC methods, improving data integrity, reducing costs, and accelerating detection times.

• Over 150 systems placed globally, with about 70% of the top 20 pharma companies as customers.

• Customers benefit from operational efficiency, labor savings, faster results, and reduced human error.

• Adoption is often driven by site-level priorities and capital expenditure timing.

Market trends and customer adoption

• High ROI projects are prioritized despite tighter budgets, benefiting Growth Direct placements.

• Repeat purchases and multi-system orders from existing customers are increasing.

• Large customers typically deploy multiple systems across sites, with timing influenced by site readiness and budget.

• Expansion within both large and small/mid-sized customer segments is a key focus.

• Multi-system orders are trending up, especially among top 20 pharma companies.

Product innovation and revenue drivers

• Sterility testing added to the platform, enabling faster, automated end-of-line QC with results in as little as three days.

• Biologics, cell, and gene therapies drive higher consumable usage per system compared to small molecules.

• Sterility offering expected to contribute to revenue growth in 2025, though sales cycles are longer for new products.

• R&D focuses on expanding platform capabilities for both revenue generation and cost reduction.